Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07388277 · ClinicalTrials.gov registry record · Phase 1
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
A Phase 1 study, sponsored by Marcela V. Maus, M.D.,Ph.D..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT07388277: Recruiting Phase 1 study, sponsored by Marcela V. Maus, M.D.,Ph.D..
NCT07388277 is a Phase 1 study that is actively recruiting participants, run by Marcela V. Maus, M.D.,Ph.D.. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07388277, a Phase 1 study, is actively recruiting participants, sponsored by Marcela V. Maus, M.D.,Ph.D..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Primary Outcome
The occurrence of DLT is the primary endpoint and will be assessed for all patients treated at the expansion dose.
Interventions
- DRUG Lymphodepletion Chemotherapy
- DRUG CC-97540
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-07-09 |
| Est. Completion | 2029-12-31 |
| Phase | Phase 1 |
What NCT07388277 shows while recruiting
NCT07388277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 2 interventions - of which Lymphodepletion Chemotherapy is the first listed.
NCT07388277 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07388277 about?
NCT07388277 is a clinical study titled "CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis". The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
What is the current status of trial NCT07388277?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-07-09. Estimated completion is 2029-12-31.
What interventions are being tested in trial NCT07388277?
The interventions under investigation include: Lymphodepletion Chemotherapy (DRUG), CC-97540 (DRUG).
Who is sponsoring clinical trial NCT07388277?
This trial is sponsored by Marcela V. Maus, M.D.,Ph.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07388277's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI